VA-REGULA
Regula, a global developer of forensic devices and identity verification solutions, has released a significant update to its operating software, Regula Forensic Studio. This major revamp enhances the functionality of forensic devices, improves usability, streamlines operations, and allows for more precise document examination.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240702630951/en/
A forensic expert examines a banknote with the help of a Regula device and Regula Forensic Studio software (Photo: Regula)
Compatible with Regula’s most recent advanced forensic devices, including the company’s flagship dual-video spectral comparator, Regula 4308, Regula Forensic Studio software facilitates manual examination of handwritten texts, banknotes, travel and identity documents, collectibles, and more. Supplied in a bundle with forensic devices and available out-of-the-box, Regula Forensic Studio can operate all Regula devices in a forensic laboratory, creating a smooth user experience and allowing for a wide range of examinations.
The new features and improvements in Regula Forensic Studio significantly elevate the user experience, as well as the convenience, speed, and accuracy of forensic examination.
Crucial examination speed and precision enhancements include:
- A new cross-platform architecture that significantly streamlines document processing and reporting, and ensures full compatibility with all popular operating systems, such as Windows, Linux, and macOS.
- The possibility of creating predefined scenarios (macros) for repetitive tasks, which makes it possible to automate the verification process for certain types of documents. For example, if an expert needs to verify a wad of banknotes, they can automatically record the sequence of checks (including all the lighting and filtering techniques) for one banknote, and auto-repeat it for the rest of the wad. Not only does this feature streamline the whole process, but also eliminates human-related errors.
- Fully automated ID verification in mere seconds through seamless integration with Regula Document Reader SDK, which instantly recognizes the document type and validates all its data from MRZs, RFID chips, barcodes, and performs available security checks.
- Enhanced integration with the Information Reference System (IRS), which makes it simple to compare an examined document to its reference image from the database. Thanks to real-time sync between RFS and the Information Reference System, the device's active light source is switched to the one used in the reference sample, and vice versa. This leads to more quick and efficient examinations.
- Automated banknote residual area measurement, a new feature that was added as a response to customers’ needs. It uses banknote references from the Regula IRS to automatically measure the undamaged area of a banknote and determine if it can be accepted by the bank.
Key usability enhancements include:
- A new intuitive user-friendly interface.
- Multi-screen support to allow users to drag and drop application tabs between monitors, which is especially convenient when working with several images.
- Colored image superimposition, a new feature that highlights different elements of two images for easier comparison.
- Pseudocolor visualization, a feature that uses substitute bright colors to highlight areas within the same color (like some indistinguishable shades of gray) for better visualization.
- Automatic detection of Machine Identification Code (MIC), a new feature that detects a unique yellow-dot pattern color laser printers and copiers leave on paper sheets. This helps identify the source of printed documents.
“In the crowded field of ID verification, Regula has distinguished itself by constantly improving, as well as adopting a customer-centric approach at the core of our research and development. The updated Regula Forensic Studio software has become notably faster and more efficient. It reflects feedback from external forensic experts and our customers, and incorporates features designed to address specific use cases and improve operations. This user-centric approach helps us boost the functionality of our solutions and meet the evolving needs of our customers in the most efficient way,” says Ihar Kliashchou, Chief Technology Officer at Regula.
To see the full list of new features and capabilities and learn more about the recent update of Regula Forensic Studio, please visit Regula’s website.
About Regula
Regula is a global developer of forensic devices and identity verification solutions. With our 30+ years of experience in forensic research and the largest library of document templates in the world, we create breakthrough technologies in document and biometric verification. Our hardware and software solutions allow over 1,000 organizations and 80 border control authorities globally to provide top-notch client service without compromising safety, security, or speed. Regula has been repeatedly named a Representative Vendor in the Gartner® Market Guide for Identity Verification.
Learn more at www.regulaforensics.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240702630951/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Pimicotinib Approved as Systemic Treatment in China for Tenosynovial Giant Cell Tumor22.12.2025 09:00:00 CET | Press release
First regulatory approval in the world for pimicotinib based on positive data from global Phase 3 MANEUVER studyIn MANEUVER, pimicotinib significantly improved objective response rate at week 25 (54% vs. 3.2% for placebo), while providing clinically meaningful and statistically significant improvements across all patient-reported outcomesWith longer-term follow-up, 3 out of 4 patients treated with pimicotinib achieved response per RECIST v1.1, and treatment continued to be well-toleratedApproval strengthens Merck’s leadership in rare tumors, with additional ongoing regulatory filings for pimicotinib underway globally Merck, a leading science and technology company, announced today that following Priority Review, the China National Medical Products Administration (NMPA) has approved pimicotinib for the treatment of adult patients with symptomatic tenosynovial giant cell tumor (TGCT) for which surgical resection will potentially cause functional limitation or relatively severe morbidity.
Incyte Japan Announces Approval of Minjuvi® (tafasitamab) in Combination with Rituximab and Lenalidomide for the Treatment of Relapsed or Refractory Follicular Lymphoma22.12.2025 08:44:00 CET | Press release
Incyte Biosciences Japan G.K. today announced approval from Japan's Ministry of Health, Labour and Welfare (MHLW) for Minjuvi® (tafasitamab) in combination with rituximab and lenalidomide for adult patients with relapsed or refractory follicular lymphoma (2L+ FL). “Today's approval of Minjuvi in combination with rituximab and lenalidomide marks a significant milestone as the first dual-targeted CD19 and CD20 immunotherapy combination for relapsed or refractory FL in Japan,” said Yasuyuki Ishida, General Manager, Incyte Biosciences Japan. “By improving progression-free survival, Minjuvi offers a chemotherapy-free option for eligible patients with relapsed or refractory disease. This approval underscores our commitment to bridging critical treatment gaps to patients and families affected by this challenging disease in Japan.” The approval is based on the pivotal Phase 3 inMIND trial, which enrolled 654 adult patients, including patients based in Japan. The study demonstrated that Minjuvi
Incyte Japan Announces Approval of Zynyz® (retifanlimab) for the First-Line Treatment of Advanced Anal Cancer22.12.2025 08:42:00 CET | Press release
Incyte Biosciences Japan G.K. today announced the Japan Ministry of Health, Labour and Welfare (MHLW) approval of Zynyz® (retifanlimab) in combination with carboplatin and paclitaxel (platinum-based chemotherapy) for the first-line treatment of advanced squamous cell carcinoma of the anal canal (SCAC). "Today's approval marks a significant milestone for patients with advanced anal cancer in Japan – the MHLW’s approval of Zynyz as the first and only first-line treatment for SCAC," said Yasuyuki Ishida, General Manager, Incyte Biosciences Japan G.K. "By offering combination therapy with chemotherapy, Zynyz provides a vital new path forward for patients facing this challenging disease, addressing a significant unmet need in cancer care for patients with SCAC and their families." The approval was based on data from the Phase 3 POD1UM-303/InterAACT2 trial evaluating Zynyz in combination with platinum-based chemotherapy (carboplatin-paclitaxel) in adult patients with metastatic or inoperable
GBC AG Analyst Coverage Report on Mexedia S.p.A. Società Benefit Completed and Published22.12.2025 08:30:00 CET | Press release
Regulatory News: Mexedia S.p.A. Società Benefit (Euronext Growth Paris: ALMEX, ISIN IT0005450819) (“Mexedia” or the “Company”) informs that the analyst coverage report prepared by GBC AG – one of the leading independent financial research firms in Germany –, developed within an issuer-sponsored research framework, has been completed and is now publicly available. The report follows the re-initiation of analyst coverage by GBC AG previously communicated by the Company and is based exclusively on publicly available information. The content, assumptions and conclusions of the report are solely attributable to the analyst. The GBC AG analyst coverage report is available on the Company’s official website at the following address: https://mexedia.com/en/financial-statements-and-reports/ and on the analyst’s website. Daniel Gilcher, Chief Financial Officer of Mexedia S.p.A. Società Benefit, stated: “The completion and publication of the analyst coverage report by GBC AG represents the conclus
Hisense Joins HEVC Advance Patent Pool22.12.2025 03:06:00 CET | Press release
Access Advance LLC, the global leader in video codec patent pool licensing, today announced that Hisense Group Holdings Co., Ltd. has joined the HEVC Advance Patent Pool as a Licensee. Hisense joins the recent additions to the Access Advance patent pools, including Xiaomi, MSI, Transsion, and expanded relationships with Huawei, HP and Sharp. Hisense, headquartered in Qingdao, China, is one of the world's largest television manufacturers, with a global presence spanning Asia, Europe, the Americas, and beyond. The company's products reach consumers in more than 160 countries and regions worldwide. "We are pleased to welcome Hisense to the HEVC Advance Patent Pool," said Peter Moller, CEO of Access Advance. "This agreement is the result of extensive engagement between our teams over a considerable period of time. Hisense's decision to join the pool reflects a recognition that transparent, efficient licensing solutions benefit both innovators and implementers across the video technology ec
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
